Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
18. Hoverd PA, Fowler CJ (1998) Desmopressin in the treatment <strong>of</strong> daytime urinary frequency in<br />
patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 65: 778-780<br />
119. Huckabee ML, Cannito MP (1999) Outcome <strong>of</strong> swallowing rehabilitation in chronic brainstem<br />
dysphagia: a retrospective evaluation. Dysphagia 14: 93-109<br />
120. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, Poewe W, Wissel J, Bain P,<br />
Glickman S, Sayer A, Richardson A, Dott C (2000) Botulinum toxin (Dysport) treatment <strong>of</strong> hip<br />
adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo<br />
controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707-712<br />
121. IFNB <strong>Multiple</strong> <strong>Sclerosis</strong> Study Group (1993) Interferon beta-1b is effective in relapsing-remitting<br />
multiple sclerosis. Clinical results <strong>of</strong> a multicentre, randomized, double-blind, placebo-controlled<br />
trial. Neurology 43:655-61<br />
122. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM (2004) Efficacy <strong>of</strong> duloxetine, a<br />
potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in<br />
rats. J Pharmacol Exp Ther 311:576-584<br />
123. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger<br />
CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL,<br />
Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham<br />
RH (1996) Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis.<br />
Ann Neurol 39:285-294<br />
124. Jacobson BH, Johnson A, Grywalsk C, Silbergleit A, Jacobson G, Benninger M (1997) The voice<br />
handicap index (VHI): development and validation. Am J Speech Lang Pathol 6:66-70<br />
125. Jacquetin B, Wyndaele J (2001) Tolterodine reduces the number <strong>of</strong> urge incontinence episodes in<br />
patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98:97-102<br />
126. Jones L, Lewis Y, Harrison J, Wiles CM (1996) The effectiveness <strong>of</strong> occupational therapy and physiotherapy<br />
in multiple sclerosis patients with ataxia <strong>of</strong> the upper limb and trunk. Clin Rehabil 10:<br />
277-282<br />
127. Jonsson A, Korfitzen EM, Heltberg A, Ravnborg MH, Byskov-Ottosen E (1993) Effects <strong>of</strong> neuropsychological<br />
treatment in patients with multiple sclerosis. Acta Neurol Scand 88:394-400<br />
128. Kalla R, Glasauer S, Schautzer F, Lehnen N, Buttner U, Strupp M, Brandt T (2004) 4-Aminopyridine<br />
improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology 62:1228-1229<br />
129. Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A (2002) Morphine responsiveness in a group <strong>of</strong><br />
well-defined multiple sclerosis patients: a study with IV Morphine. Eur J Pain 6:69-80<br />
130. Kappos L, Polman CH, Freedman <strong>MS</strong>, Edan G, Hartung HP, Miller DH, Montalban X, Barkh<strong>of</strong> F,<br />
Bauer L, Jokobs P, Pohl C, Sandbrink R (2006) <strong>Treatment</strong> with interferon beta-1b delays conversion<br />
to clinically definite and McDonald <strong>MS</strong> in patients with clinically isolated syndromes. Neurology<br />
67: Aug 30; [Epub ahead <strong>of</strong> print]<br />
49 E<strong>MS</strong>P, <strong>Symptomatic</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Multiple</strong> <strong>Sclerosis</strong>, December 2006 - revised in April 2008
Change language